Skip to main content

The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on Clinical Outcomes After Spinal Surgery: A Systematic Review and Meta-Analysis

In brief

GLP-1 drugs link to 20% to 38% lower odds of spinal fusion failure

In 36 retrospective studies covering 435,085 patients, perioperative GLP-1 drug use was associated with lower rates of failed spinal fusion at follow-up from 6 months to 3 years, but not at 90 days. The studies also found fewer revisions at selected intervals, alongside higher risks of low blood sugar and adjacent segment disease; very-low-certainty evidence cannot show the drugs caused these outcomes.

Journal
Global spine journal (Q1)
Published
16 November 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Xunpei Xu, Xuanrui Zhang, Zhuyun Cai, Yue Yang, Tao Lin, Zheng Zhang, et al.
PMID
43038446
DOI
10.1177/21925682261509580

Why clinicians should know about it

  • Picked for Spine Surgery (top studies of the week, 22 November 2026): Spine surgery outcomes, pseudarthrosis, revision, and complications

Abstract

Study designsystematic review and meta-analysis.ObjectiveTo evaluate the association between perioperative glucagon-like peptide-1 receptor agonists (GLP-1RAs) use and clinical outcomes after spine surgery.MethodsPubMed, MEDLINE, Embase, Web of Science, and the Cochrane Library were searched through July 31, 2026. Comparative studies of adults undergoing spine surgery with versus without perioperative GLP-1RA exposure were pooled using random-effects models. Risk of bias was assessed with the Newcastle-Ottawa Scale and certainty with GRADE.ResultsThirty-six retrospective cohorts involving 435,085 patients were included. GLP-1RA use was not associated with pseudarthrosis at 90 days (RR, 0.99; 95% CI, 0.25-3.98), but was associated with lower risk at 6 months (RR, 0.62; 95% CI, 0.56-0.68), 1 year (RR, 0.65; 95% CI, 0.61-0.69), 2 years (RR, 0.77; 95% CI, 0.66-0.89), and 3 years (RR, 0.80; 95% CI, 0.69-0.92). Revision risk was lower at 6 months and 2 years. GLP-1RA use was also associated with lower risks of selected systemic, infectious, and wound complications and reduced healthcare utilization, but with higher risks of hypoglycemia and adjacent segment disease.ConclusionsIn separate follow-up-specific analyses, GLP-1RA exposure was associated with lower pseudarthrosis and revision risks at selected intervals and with several other postoperative outcomes. These estimates do not establish a temporal drug effect or distinguish direct pharmacologic effects from weight loss, improved glycemic control, or confounding. Heterogeneity, possible overlapping cohorts, and very-low-certainty observational evidence preclude causal or treatment recommendations.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.